Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy.
Savin gives an overview of what the company does, as well as its current operations and its financial situation.
He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India.